Guidelines for the diagnosis, prevention and management of osteoporosis

Reumatismo

Volumn 68, Issue 1, 2016, Pages 1-39

  Rossini, Maurizio ^a   Adami, S ^a   Bertoldo, F ^a   Diacinti, D ^a   Gatti, D ^a   Giannini, S ^a   Giusti, A ^a   Malavolta, N ^a   Minisola, S ^a   Osella, G ^a   Pedrazzoni, M ^a   Sinigaglia, L ^a   Viapiana, O ^a   Isaia, G C ^a  

^a Italian Society of Rheumatology SIR   (Italy)

Author keywords

Dual energy x ray absorptiometry; Fractures; Guidelines; Osteoporosis; Risk factors

Indexed keywords

ALENDRONIC ACID; CATHEPSIN K; CLODRONIC ACID; CORTICOSTEROID; DENOSUMAB; ETIDRONIC ACID; FUROSEMIDE; GLUCOCORTICOID; NERIDRONIC ACID; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; ZOLEDRONIC ACID;

AGING; ALBRIGHT SYNDROME; APOPTOSIS; ARTICLE; BONE BROWN TUMOR; BONE DENSITOMETRY; BONE DENSITY; BONE TUMOR; CALCIUM INTAKE; CHRONIC KIDNEY DISEASE; COLIA1 GENE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIFFERENTIAL DIAGNOSIS; DUAL ENERGY X RAY ABSORPTIOMETRY; ECHOGRAPHY; ER GENE; FAMILY HISTORY; FRAGILITY FRACTURE; GENE; GENETIC POLYMORPHISM; HORMONE SUBSTITUTION; HUMAN; HYPERCALCEMIA; KIDNEY CALCIFICATION; KYPHOPLASTY; NEPHROLITHIASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN TRANSPLANTATION; OSTEOGENESIS IMPERFECTA; OSTEOPOROSIS; PARATHYROIDECTOMY; PERCUTANEOUS VERTEBROPLASTY; PHYSICAL ACTIVITY; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PRIMARY HYPERPARATHYROIDISM; RISK ASSESSMENT; RISK FACTOR; SECONDARY OSTEOPOROSIS; SENILE OSTEOPOROSIS; VDR GENE; VITAMIN SUPPLEMENTATION; EVIDENCE BASED MEDICINE; INCIDENCE; ITALY; MEDICAL SOCIETY; META ANALYSIS (TOPIC); OSTEOPOROTIC FRACTURES; PHOTON ABSORPTIOMETRY; PROCEDURES; RHEUMATOLOGY;

ABSORPTIOMETRY, PHOTON; BONE DENSITY; EVIDENCE-BASED MEDICINE; HUMANS; INCIDENCE; ITALY; META-ANALYSIS AS TOPIC; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; RHEUMATOLOGY; RISK ASSESSMENT; RISK FACTORS; SOCIETIES, MEDICAL;

EID: 84975705387     PISSN: 00487449     EISSN: 22402683     Source Type: Journal    
DOI: 10.4081/reumatismo.2016.870     Document Type: Article

References (120)

1. Hernlund E, Svedbom A, Ivergard M, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2013; 8: 136.
2. Kanis JA, Hans D, Cooper C, et al. Interpretation and use of FRAX in clinical practice. Osteoporos Int. 2011; 22: 2395-411.
3. Morin SN, Lix LM, Leslie WD. The importance of previous fracture site on osteoporosis diagnosis and incident fractures in women. J Bone Miner Res. 2014; 29: 1675-80.
4. Hodsman AB, Leslie WD, Tsang JF, Gamble GD. 10-year probability of recurrent fractures following wrist and other osteoporotic fractures in a large clinical cohort: an analysis from the Manitoba Bone Density Program. Arch Intern Med. 2008; 168: 2261-7.
5. Gehlbach S, Saag KG, Adachi JD, et al. Previous fractures at multiple sites increase the risk for subsequent fractures: The global longitudinal study of osteoporosis in women. J Bone Miner Res. 2012; 27: 645-53.
6. Kanis JA, Johansson H, Oden A, et al. A family history of fracture and fracture risk: a meta-analysis. Bone. 2004; 35: 1029-37.
7. Hippisley-Cox J, Coupland C. Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. BMJ. 2012; 344: e3427.
8. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a meta-analysis. Osteoporos Int. 2007; 18: 427-44.
9. Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007; 166: 495-505.
10. Fan Y, Wei F, Lang Y, Liu Y. Diabetes mellitus and risk of hip fractures: a meta-analysis. Osteoporos Int. 2016; 27: 219-28.
11. van den Bos F, Speelman AD, Samson M, et al. Parkinson’s disease and osteoporosis. Age Ageing. 2013; 42: 156-62.
12. Dennison EM, Compston JE, Flahive J, et al. Effect of co-morbidities on fracture risk: findings from the global longitudinal study of osteoporosis in women (GLOW). Bone. 2012; 50: 1288-93.
13. Broy SB, Tanner SB; FRAX(R) Position Development Conference Members. Official positions for FRAXR clinical regarding rheumatoid arthritis: from joint official positions development conference of the international society for clinical densitometry and international osteoporosis foundation on FRAXR. J Clin Densitom. 2011; 14: 184-9.
14. Shiau S, Broun EC, Arpadi SM, Yin MT. Incident fractures in HIV-infected individuals: a systematic review and meta-analysis. AIDS. 2013; 27: 1949-57.
15. Dong HV, Cortes YI, Shiau S, Yin MT. Osteoporosis and fractures in HIV/hepatitis C virus coinfection: a systematic review and meta-analysis. AIDS 2014; 28: 2119-31.
16. Yeh MW, Ituarte PH, Zhou HC, et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab. 2013; 98: 1122-9.
17. Fraser WD. Hyperparathyroidism. Lancet. 2009; 374: 145-58.
18. Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab. 2014; 99: 3561-9.
19. Gunn IR, Gaffeny D. Clinical and laboratory features of calcium-sensing receptor disorders: a systematic review. Ann Clin Biochem. 2004; 41: 441-58.
20. Mollerup CL, Vestergaard P, Frokjaer VG, et al. Risk of renal stone events in primary hyperparathyroidism before and after parathyroid surgery: controlled retrospective follow-up study. BMJ. 2002; 325: 807.
21. Vestergaard P, Mollerup CL, Frokjaer VG, et al. Cohort risk of fracture before and after surgery for primary hyperparathyroidism. BMJ. 2000; 321: 598-602.
22. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007; 18: 1319-28.
23. Seibel MJ, Cooper MS, Zhou H. Glucocorticoidinduced osteoporosis: mechanisms, management, and future perspectives. Lancet Diabetes Endocrinol. 2013; 1: 59-70.
24. Yang IA, Clarke MS, Sim EH, Fong KM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012; 7: CD002991.
25. Mattishent K, Thavarajah M, Blanco P, et al. Meta-review: adverse effects of inhaled corticosteroids relevant to older patients. Drugs. 2014; 74: 539-47.
26. Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax. 2011; 66: 699-708.
27. Van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002; 13: 777-87.
28. Kanis JA, Johansson H, Oden A, et al. A metaanalysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004; 19: 893-9.
29. Heffernan MP, Saag KG, Robinson JK, Callen JP. Prevention of osteoporosis associated with chronic glucocorticoid therapy. JAMA. 2006; 295: 1300-3.
30. Homik J, Suarez-Almazor ME, Shea B, et al. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev. 2000; (2): CD000952.
31. Laatikainen AK, Kroger HP, Tukiainen HO, et al. Bone mineral density in perimenopausal women with asthma: a population-based cross-sectional study. Am J Respir Crit Care Med. 1999; 159: 1179-85.
32. Crawford BA, Liu PY, Kean MT, et al. Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab. 2003; 88: 3167-76.
33. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med. 1998; 339: 292-9.
34. Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European corticosteroid-induced osteoporosis treatment study. J Bone Miner Res. 2000; 15: 1006-13.
35. Reid DM, Devogelaer JP, Saag K, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009; 373: 1253-63.
36. Homik J, Cranney A, Shea B, et al. Bisphosphonates for steroid induced osteoporosis. Cochrane Database Syst Rev. 2000; (2): CD001347.
37. Rossini M, Orsolini G, Viapiana O, et al. Bisphosphonates in the treatment of glucocorticoid-induced osteoporosis: pros. Endocrine. 2015; 49: 620-7.
38. Saag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-sixmonth results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009; 60: 3346-55.
39. Dore RK, Cohen SB, Lane NE, et al. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis. 2010; 69: 872-5.
40. Nyandege AN, Slattum PW, Harpe SE. Risk of fracture and the concomitant use of bisphosphonates with osteoporosis-inducing medications. Ann Pharmacother. 2015; 49: 437-47.
41. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014; 25: 2359-81.
42. Mazziotti G, Canalis E, Giustina A. Drug-induced osteoporosis: mechanisms and clinical implications. Am J Med. 2010; 123: 877-84.
43. Kwok CS, Yeong JK, Loke YK. Meta-analysis: risk of fractures with acid-suppressing medication. Bone. 2011; 48: 768-76.
44. Abrahamsen B, Rubin KH, Eiken PA, et al. Characteristics of patients who suffer major osteoporotic fractures despite adhering to alendronate treatment: a National Prescription registry study. Osteoporos Int. 2013; 24: 321-8.
45. Turner MR, Camacho X, Fischer HD, et al. Levothyroxine dose and risk of fractures in older adults: nested case-control study. BMJ. 2011; 342: d2238.
46. Meier C, Kraenzlin ME, Bodmer M, et al. Use of thiazolidinediones and fracture risk. Arch Intern Med. 2008; 168: 820-5.
47. Miziak B, Blaszczyk B, Chroscinska-Krawczyk M, et al. The problem of osteoporostic in epileptic patients taking antiepileptic drugs. Expert Opin Drug Saf. 2014; 13: 935-46.
48. Krol C, Dekkers M, Kroon M. Longitudinal changes in BMD and fracture risk in orthotopic liver transplant recipients not using bone-modifying treatment. J Bone Miner Res. 2014; 29: 1763-9.
49. Tufano A, Coppola A, Contaldi P, et al. Oral anticoagulant drugs and the risk of osteoporosis: new anticoagulants better than old? Semin Thromb Hemost. 2015; 41: 382-8.
50. Vanderschueren D, Laurent MR, Claessens F, et al. Sex steroid actions in male bone. Endocr Rev. 2014; 35: 906-60.
51. Shao YH, Moore DF, Shih W, et al. Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications. BJU Int. 2013; 111: 745-52.
52. Hadji P, Gnant M, Body JJ, et al. Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention? Cancer Treat Rev. 2012; 38: 798-806.
53. Kwan ML, Lo JC, Tang L, et al. Bone health history in breast cancer patients on aromatase inhibitors. PLoS One. 2014; 9: e111477.
54. Zaman K, Thurlimann B, Huober J, et al. Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). Ann Oncol. 2012; 23: 1474-81.
55. Diamond TH, Higano CS, Smith MR, et al. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer. 2004; 100: 892-9.
56. Hussain SA, Weston R, Stephenson RN, et al. Immediate dual energy Xray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation. BJU. 2003; 92: 690-4.
57. Bouvard B, Hoppe E, Soulie P, et al. High prevalence of vertebral fractures in women with breast cancer starting aromatase inhibitor therapy. Ann Oncol. 2012; 23: 1151-6.
58. Coleman R, Body JJ, Aapro M, et al. Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2014; 25: iii124-37.
59. Rizzoli R, Body JJ, Brandi ML, et al. Cancer-associated bone disease. Osteoporos Int. 2013; 24: 2929-53.
60. Coleman R, de Boer R, Eidtmann H, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol. 2013; 24: 398-405.
61. Gnant M, Pfeiler G, Dubsky PC, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015; 386: 433-43.
62. Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009; 361: 745-55.
63. Greenspan SL, Nelson JB, Trump DL, et al. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. J Clin Oncol. 2008; 26: 4426-34.
64. Forbes JF, Cuzick J, Buzdar A, et al. Effect of anastrozole and tamixifene as adjuvant treatament for early-stage breast cancer: 100-months analysis of the ATAC trial. Lancet Oncol. 2008; 9: 45-53.
65. Tentori F, McCullough K, Kilpatrick RD, et al. High rates of death and hospitalization follow bone fracture among hemodialysis patients. Kidney Int. 2014; 85: 166-73.
66. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009; 113: S1-130.
67. Chauhan V, Ranganna KM, Chauhan N, et al. Bone disease in organ transplant patients: pathogenesis and management. Postgrad Med. 2012; 124: 80-90.
68. Kulak CA, Borba VZ, Kulak J Jr, Custodio MR. Osteoporosis after transplantation. Curr Osteoporos Rep. 2012; 10: 48-55.
69. Dalle Carbonare L, Zanatta M, Braga V, et al. Densitometric threshold and vertebral fractures in heart transplant patients. Transplantation. 2011; 92: 106-11.
70. Giannini S, Sella S, Silva Netto F, et al. Persistent secondary hyperparathyroidism and vertebral fractures in kidney transplantation: role of calcium-sensing receptor polymorphisms and vitamin D deficiency. J Bone Miner Res. 2010; 25: 841-8.
71. Schousboe JT, Shepherd JA, Bilezikian JP, Baim S. Executive summary of the 2013 ISCD position development conference on bone densitometry. J Clin Densit. 2013; 16: 455-67.
72. Kanis JA, McCloskey EV, Johansson H, et al. Scientific advisory board of the european society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO) and the committee of scientific advisors of the international osteoporosis foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013; 24: 23-57.
73. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014; 25: 2359-81.
74. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993; 8: 1137-48.
75. Schousboe JT, Debold CR. Reliability and accuracy of vertebral fracture assessment with densitometry compared to radiography in clinical practice. Osteoporos Int. 2006; 17: 281-9.
76. Rossini M, Viapiana O, Idolazzi L, et al. Improvements in the management of rheumatic patients from vertebral image obtained through DXA. Reumatismo. 2006; 58: 253-60.
77. Ferrar L, Jiang G, Clowes JA, et al. Comparison of densitometric and radiographic vertebral fracture assessment using the algorithm-based qualitative (ABQ) method in postmenopausal women at low and high risk of fracture. J Bone Miner Res. 2008; 23: 103-11.
78. Bonnet N, Beneton M, Kanis JA, Charlesworth D. Vertebral fracture assessment (VFA) with a densitometer predicts future fractures in elderly women unselected for osteoporosis. J Bone Miner Res. 2008; 23: 1561-8.
79. Fuerst T, Wu C, Genant HK, et al. Evaluation of vertebral fracture assessment by dual X-ray absorptiometry in a multicenter setting. Osteoporos Int. 2009; 20: 1199-205.
80. Hospers IC, van der Laan JG, Zeebregts CJ, et al. Vertebral fracture assessment in supine position: comparison by using conventional semiquantitative radiography and visual radiography. Radiology. 2009; 251: 822-8.
81. Buehring B, Krueger D, Checovich M, et al. Vertebral fracture assessment: impact of instrument and reader. Osteoporos Int. 2010; 21: 487-94.
82. Jager PL, Jonkman S, Koolhaas W, et al. Combined vertebral fracture assessment and bone mineral density measurement: a new standard in the diagnosis of osteoporosis in academic populations. Osteoporos Int. 2011; 22: 1059-68.
83. Diacinti D, Del Fiacco R, Pisani D, et al. Diagnostic performance of vertebral fracture assessment by the lunar iDXA scanner compared to conventional radiography. Calcif Tissue Int. 2012; 91: 335-42.
84. El Maghraoui A, Rezqi A, Mounach A, et al. Systematic vertebral fracture assessment in asymptomatic postmenopausal women. Bone. 2013; 52: 176-80.
85. Diacinti D, Pisani D, D’Avanzo M, et al. Reliability of vertebral fractures assessment (VFA) in children with osteogenesis imperfecta. Calcif Tissue Int. 2015; 96: 307-12.
86. Rosen HN, Vokes TJ, Malabanan AO, et al. The official positions of the international society for clinical densitometry: vertebral fracture assessment. J Clin Densit. 2013; 16: 482-8.
87. Abrahamsen B, van Staa T, Ariely R, et al. Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int. 2009; 20: 1633-50.
88. Watts NB, Adler RA, Bilezikian JP, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012; 97: 1802-22.
89. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000; 343: 604-10.
90. Boonen S, Orwoll ES, Wenderoth D, et al. Onceweekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, doubleblind, multicenter study. J Bone Miner Res. 2009; 24: 719-25.
91. Boonen S, Orwoll E, Magaziner J, et al. Onceyearly zoledronic acid in older men compared with women with recent hip fracture. J Am Geriatr Soc. 2011; 59: 2084-90.
92. Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003; 18: 9-17.
93. Langdahl BL, Teglbjarg CS, Ho PR, et al. A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. J Clin Endocrinol Metab. 2015; 100: 1335-42.
94. Kaufman JM, Audran M, Bianchi G, et al. Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men. J Clin Endocrinol Metab. 2013; 98: 592-601.
95. Varenna M, Bertoldo F, Di Monaco M, et al. Safety profile of drugs used in the treatment of osteoporosis: a systematical review of the literature. Reumatismo. 2013; 65: 143-66.
96. Rossini M, Adami G, Adami S, et al. Safety issues and adverse reactions with osteoporosis management. Expert Opin Drug Saf. 2016; 15: 321-32.
97. Adami S, Romagnoli E, Carnevale V, et al. [Guidelines on prevention and treatment of vitamin D deficiency. Italian Society for Osteoporosis, Mineral Metabolism and Bone Diseases (SIOMMMS)]. Reumatismo. 2011; 63: 129-47. [Article in Italian]
98. Rossini M, Gatti D, Viapiana O, et al. Vitamin D and rheumatic diseases. Reumatismo. 2014; 66: 153-70.
99. Adami S, Giannini S, Bianchi G, et al. Vitamin D status and response to treatment in postmenopausal osteoporosis. Osteoporos Int. 2009; 20: 239-44.
100. Rossini M, Adami S, Viapiana O, et al. Dose-dependent short-term effects of single high doses of oral vitamin D(3) on bone turnover markers. Calcif Tissue Int. 2012; 91: 365-9.
101. Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA. 2010; 303: 1815-22.
102. Institute of Medicine (US). Committee to review dietary reference intakes for vitamin D and calcium. In: Ross AC, Taylor CL, Yaktine AL, Del Valle HB, eds. Dietary reference intakes for calcium and vitamin D. Washington, DC: National Academies Press; 2011.
103. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J Clin Endocrinol Metab. 2012; 97: 1153-8.
104. Rizzoli R, Boonen S, Brandi ML, et al. Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Curr Med Res Opin. 2013; 29: 305-13.
105. Adami S, Bertoldo F, Brandi ML, et al. [Guidelines for the diagnosis, prevention and treatment of osteoporosis]. Reumatismo. 2009; 61: 260-84. [Article in Italian]
106. Adami S, Bianchi G, Brandi ML, et al. Validation and further development of the WHO 10-year fracture risk assessment tool in Italian postmenopausal women: project rationale and description. Clin Exp Rheumatol. 2010; 28: 561-70.
107. Bonaccorsi G, Fila E, Cervellati C, et al. Assessment of fracture risk in a population of postmenopausal italian women: a comparison of two different tools. Calcif Tissue Int. 2015; 97: 50-7.
108. Adami S, Bertoldo F, Gatti D, et al. Treatment thresholds for osteoporosis and reimbursability criteria: perspectives associated with fracture risk-assessment tools. Calcif Tissue Int. 2013; 93: 195-200.
109. Yang SD, Chen Q, Wei HK, et al. Bone fracture and interaction between bisphosphonates and proton pump inhibitors: a meta-analysis. Int J Clin Exper Med. 2015; 8: 4899-910.
110. Black DM, Reid IR, Cauley JA, et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the Horizon-Pivotal Fracture TRIAL (PFT). J Bone Miner Res. 2015; 30: 934-44.
111. Boonen S, Reginster J-Y, Kaufman J-M, et al. Fracture risk and zoledronic acid therapy in men with Osteoporosis. New Engl J Med. 2012; 367: 1714-23.
112. Varenna M, Adami S, Rossini M, et al. Treatment of complex regional pain syndrome type I with Neridronate: a randomized, double-blind, placebo controlled study. Rheumatology (Oxford). 2013; 52: 534-42.
113. Miller PD, Jamal SA, Evenepoel P, et al. Renal safety in patients treated with bisphopsphonates for osteoporosis: a review. J Bone Miner Res. 2013; 28: 2049-59.
114. Bedogni A, Campisi G, Fusco V, Agrillo A. Raccomandazioni clinico-terapeutiche su osteonecrosi dei mascellari associata a bisfosfonati e sua prevenzione. Padova: CLEUP; 2013.
115. Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American society for bone and mineral research. J Bone Miner Res. 2014; 29: 1-23.
116. Rossini M, Lello S, Sblendorio I, et al. Profile of bazedoxifene/conjugated estrogens for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fracture. Drug Des Devel Ther. 2013; 7: 601-10.
117. Sharifi M, Lewiecki EM. Conjugated estrogens combined with bazedoxifene: the first approved tissue selective estrogen complex therapy. Expert Rev Clin Pharmacol. 2014; 7: 281-91.
118. Mirkin S, Ryan KA, Chandran AB, Komm BS. Bazedoxifene/conjugated estrogens for managing the burden of estrogen deficiency symptoms. Maturitas. 2014; 77: 24-31.
119. Valera MC, Gourdy P, Tremollieres F, et al. From the Women’s Health Initiative to the combination of estrogen and selective ER modulators to avoid progestin addition. Maturitas. 2015; 82: 274-7.
120. Pinkerton JV, Harvey JA, Lindsay R, et al. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. J Clin Endocrinol Metab. 2014; 99: E189-98.